scholarly journals Advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating Wnt/β‐catenin signalling pathway via DNA methylation

2020 ◽  
Vol 53 (6) ◽  
Author(s):  
Yong Li ◽  
Lang Wang ◽  
Maorui zhang ◽  
Kui Huang ◽  
Zhihao Yao ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Stem Cells ◽  
Osteogenic Differentiation ◽  
Advanced Glycation End Products ◽  
Signalling Pathway ◽  
Adipose Derived Stem Cells ◽  
Advanced Glycation ◽  
Differentiation Potential ◽  
Glycation End Products ◽  
End Products

scholarly journals Advanced Glycation End Products Receptor DNA Methylation Is Associated with Immune Infiltration and Prognosis of Lung adenocarcinoma and lung squamous cell carcinoma

2021 ◽  
Author(s):  
Jun Yang ◽  
Xiaohui Chen ◽  
Mingqiang Lin ◽  
Mengyan Zhang ◽  
Zhiping Wang ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Squamous Cell Carcinoma ◽  
Lung Adenocarcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Advanced Glycation End Products ◽  
Lung Squamous Cell Carcinoma ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Abstract Background: Lung cancer has become the leading cause of cancer-related deaths worldwide with a rising trend of incidence and mortality. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) account for the major numbers, which should be paid enough attention. Advanced glycation end products receptor (AGER) is a multi-ligand receptor that interacts with a wide range of ligands. Previous studies have shown that abnormal AGER expression is closely related to immune infiltration and tumorigenesis. Nevertheless, the AGER DNA methylation relationship between prognosis and infiltrating immune cells in LUAD and LUSC is still unclear. Results: Compared with the normal lung tissues, the expression level of AGER was significantly reduced in LUAD and LUSC. Low expression of AGER was markedly correlated with histology, stage, lymph node metastasis and Tumor protein 53 (TP53) mutation and could be used as a potential indicator of poor prognosis of LUAD and LUSC. Further analysis showed that copy number variation (CNV), mutation and DNA methylation involved in the low level of AGER. Additionally, we found that AGER DNA hypermethylation meant a worse prognosis in LUAD and LUSC. In addition, we also found that hypermethylated AGER was significantly correlated with tumor infiltrating lymphocytes. Conclusion: AGER may be a candidate for the prognostic biomarker of LUAD and LUSC related with tumor immune microenvironment.

Stem Cells in Head and Neck Cancers Pathogenesis: Are Advanced Glycation End Products (AGEs) Involved?

2018 ◽  
Vol 04 (02) ◽  
Author(s):  
Petrescu Bianca Nausica ◽  
Babtan Anida Maria ◽  
Soritau Olga ◽  
Buhate Dan ◽  
Ionel Anca ◽  
...  
Keyword(s):  
Stem Cells ◽  
Head And Neck ◽  
Advanced Glycation End Products ◽  
Head And Neck Cancers ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products
Sign in / Sign up

Export Citation Format

Share Document